Abstract
The aim of this study was to evaluate the safety and efficacy of aprepitant when used prophylactically to prevent nausea and vomiting during cyclophosphamide-based conditioning regimens. The primary objective of this study was to determine if there was a difference in the number of emesis-free days in patients who received aprepitant as compared to those who received placebo. This prospective, randomized, double blind, placebo-controlled study was performed in 40 adult patients who received a cyclophosphamide-containing HSCT conditioning regimen. Twenty patients were randomized to receive aprepitant, ondansetron, and dexamethasone, and 20 were randomized to receive placebo, ondansetron, and dexamethasone. Complete response (CR) was defined as the absence of emesis and the absence of mild to moderate nausea. The average number of emesis-free days was 14.25 (standard deviation 1.48 days) in the aprepitant group compared to 12.45 days (standard deviation 2.16 days) for patients in the placebo group. Eight patients (40%) in the aprepitant group achieved CR as compared to four patients (20%) in the placebo group. In the setting of cyclophosphamide-containing conditioning regimens, the addition of aprepitant to a standard antiemetic regimen decreased the incidence of emesis as compared to placebo. Aprepitant was well tolerated.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fox-Geiman MP, Fisher SG, Kiley K, Fletcher-Gonzalez D, Porter N, Stiff P. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:596–603.
Perez EA, Tiemeier T, Solberg LA. Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT(3) regimen and literature review. Support Care Cancer. 1999;7:413–24.
Basch E, Prestrud AA, Hesketh PJ, Kris MG, Geyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189–98.
Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology guideline update. J Clin Oncol. 2017;35:3240–61.
Hesketh PJ, Bohlke K, Lyman GH, Basch E, Chesney M, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol. 2016;34:381–6.
Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27:v119–33.
Aprepitant [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2017. https://www.merck.com/product/usa/pi_circulars/e/emend/emend_pi.pdf
de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoquang-Ma J, Elmer M, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer. 2004;40:403–10.
Bubalo JS, Cherala G, McCune JS, Munar MY, Tse S, Maziarz R. Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. J Clin Pharmacol. 2012;52:586–94.
Bubalo J, Seelig F, Karbowicz S, Maziarz RT. Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:439–45.
Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L. Determinants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol. 1997;15:116–23.
Abbott B, Ippoliti C, Hecth D, Bruton J, Whaley B, Champlin R. Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation. Bone Marrow Transplant. 2000;25:1279–83.
Yen CC, Hsieh RK, Chiou TJ, Liu JH, Fang FS, Wang WS, et al. Navoban (tropisetron, ICS 205-930) and dexamethasone combination in the prevention of vomiting for patients receiving preconditioning high-dose chemotherapy before marrow transplantation. Jpn J Clin Oncol. 1998;28:129–33.
Paul B, Trovato JA, Thompson J, Badros AZ, Goloubeva O. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract. 2010;16:45–51.
Pielichowski W, Barzal J, Gawronski K, Mlot B, Oborska S, Wasko-Grabowska A, et al. A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transplant Proc. 2011;43:3107–10.
Stiff PJ, Fox-Geiman MP, Kiley K, Rychlik K, Parthasarathy M, Fletcher-Gonzalez D, et al. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant. 2013;19:49–55. e41
Szer J, Grigg AP, Roberts AW, Raunow H. Aprepitant in the prevention of acute and delayed nausea and vomiting following haematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant. 2006;37:S112.
Bechtel TP, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM Jr, et al. Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma. Support Care Cancer. 2014;22:2911–6.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Merck & Co., Inc. provided research funding to JB and provided study drug. All remaining authors declare that they have no conflict of interest.
Appendices
Appendix A. Standard antiemetic therapy for study conditioning chemotherapy regimens
Conditioning chemotherapy regimens | Standard antiemetic therapy |
BU(16)-CY(120) | Â |
 Busulfan (BU) PO 16 mg/kg over 4 days | Ondansetron 8 mg PO Q 6 h × 4 days with BU |
 Cyclophosphamide (CY) 120 mg/kg over 2 days | Ondansetron 8 mg IV Q 12 h × 5 doses with CY |
 6 days total therapy | Dexamethasone 20 mg IV/PO Q 24 h × 2 days before CY |
BU(14)-CY(150) | Â |
 Busulfan PO 14 mg/kg over 3.5 days | Ondansetron 8 mg PO Q 6 h × 4 days with BU |
 Cyclophosphamide 150 mg/kg over 3 days | Ondansetron 8 mg IV Q 12 h × 7 doses with CY |
 7 days total therapy | Dexamethasone 20 mg IV/PO Q 24 h × 3 days before CY |
BU(16)-CY(200) | Â |
 Busulfan PO 16 mg/kg over 4 days | Ondansetron 8 mg PO Q 6 h × 4 days with BU |
 Cyclophosphamide 200 mg/kg over 4 days | Ondansetron 8 mg IV Q 12 h × 9 doses with CY |
 8 days total therapy | Dexamethasone 20 mg IV/PO Q 24 h × 4 days before CY |
CY-TBI-12 | Â |
 TBI 1200 cGy over 4 days in 8 fractions | Ondansetron 8 mg PO Q 12 h prior to TBI × 4 days |
 Cyclophosphamide 120 mg/kg over 2 days | Ondansetron 8 mg IV Q 12 h × 5 doses with CY |
 6 days total therapy | Dexamethasone 20 mg IV/PO Q 24 h × 6 days in AM |
CY-TBI-14 | Â |
 TBI 1400 cGy over 4 days in 8 fractions | Ondansetron 8 mg PO Q 12 h prior to TBI × 4 days |
 Cyclophosphamide 120 mg/kg over 2 days | Ondansetron 8 mg IV Q 12 h × 5 doses with CY |
 6 days total therapy | Dexamethasone 20 mg IV/PO Q 24 h × 6 days in AM |
Appendix B. Quality of life (QOL)/nausea 100 mm visual analogue scale (VAS) assessment form
QUALITY OF LIFE WITH NAUSEA EVALUATION FORM
Instructions
Below are several questions related to your feelings of well-being. To answer the question make a line/slash mark at the point on the line that best represents how you are feeling at the present time. Please refer to the last 24 hour time period when answering each question.
Example:
1. Do you have nausea?
never nauseated ___|___ nauseated all the time
The place marked above would indicate that you feel nauseated over half of the time.
1. Do you have nausea? never nauseated ____ nauseated all the time
2. Do you vomit?
never vomit ____ vomit all the time
3. Have you had any changes in taste?
no changes in taste ____ many changes in taste
4. How much of an appetite do you have?
no appetite at all ____ more appetite than usual
5. Is the amount you eat sufficient for your needs?
not at all sufficient ____ completely sufficient
****For Data Management Use ONLY****
Date completed   BMT Day   Patient Initials   Patient Number   Protocol
XX-XX-XX Â Â Â Â Â XX Â Â Â Â Â Â Â XXX Â Â Â Â Â Â Â Â XX Â Â Â Â Â Â Â Â Â Â XX
Rights and permissions
About this article
Cite this article
Bubalo, J., Mulverhill, K., Meyers, G. et al. A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT). Bone Marrow Transplant 53, 1010–1018 (2018). https://doi.org/10.1038/s41409-018-0106-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-018-0106-8
This article is cited by
-
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting
Supportive Care in Cancer (2024)
-
Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation
Clinical Hematology International (2022)
-
Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study
Annals of Hematology (2022)
-
Nausea and vomiting during post-transplantation cyclophosphamide administration
International Journal of Hematology (2020)